Association between gene variants and response to buprenorphine maintenance treatment

Psychiatry Research

Volumn 215, Issue 1, 2014, Pages 202-207

  Gerra, Gilberto ^a   Somaini, Lorenzo ^b   Leonardi, Claudio ^c   Cortese, Elena ^c   Maremmani, Icro ^d   Manfredini, Matteo ^e   Donnini, Claudia ^e  

^a United Nations Office on Drugs and Crime Austria   (Austria)

^b Health Local Unit BI   (Italy)

^c Addiction Treatment Center   (Italy)

^d UNIVERSITY OF PISA   (Italy)

^e UNIVERSITY OF PARMA   (Italy)

Author keywords

Buprenorphine; Gene variants; K opioid receptors; Maintenance treatment

Indexed keywords

BUPRENORPHINE; DIAMORPHINE; DOPAMINE TRANSPORTER; GUANINE; KAPPA OPIATE RECEPTOR; MU OPIATE RECEPTOR; THYMINE;

ADULT; ARTICLE; BEHAVIOR DISORDER; CAUCASIAN; CLINICAL EFFECTIVENESS; CONTROLLED STUDY; DAT1 GENE; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG MECHANISM; DRUG RESPONSE; FEMALE; GENE; GENE FREQUENCY; GENETIC VARIABILITY; GENOTYPE; HEROIN DEPENDENCE; HUMAN; MAINTENANCE THERAPY; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; NUCLEIC ACID BASE SUBSTITUTION; OPKR1 GENE; PATIENT CODING; PATIENT DROPOUTS; PERSONALITY DISORDER; PRIORITY JOURNAL; REINFORCEMENT; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT DURATION; TREATMENT OUTCOME; WESTERN EUROPE;

BUPRENORPHINE; GENE VARIANTS; K OPIOID RECEPTORS; MAINTENANCE TREATMENT;

ADULT; ALLELES; BUPRENORPHINE; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; FEMALE; GENOTYPE; HEROIN DEPENDENCE; HUMANS; MALE; MIDDLE AGED; NARCOTICS; OPIATE SUBSTITUTION TREATMENT; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, OPIOID, KAPPA; TREATMENT OUTCOME;

EID: 84892846481     PISSN: 01651781     EISSN: 18727123     Source Type: Journal    
DOI: 10.1016/j.psychres.2013.11.001     Document Type: Article

References (50)

1. Belding M.A., McLellan A.T., Zanis D.A., Incmikoski R. Characterizing "nonresponsive" methadone patients. Journal of Substance Abuse Treatment 1998, 15:485-492.
2. Bovasso G., Cacciola J. The long-term outcomes of drug use by methadone maintenance patients. Journal of Behavioral Health Services and Research 2003, 30:290-303.
3. Barratt D.T., Coller J.K., Somogyi A.A. Association between the DRD2 A1 allele and response to methadone and buprenorphine maintenance treatments. American Journal of Medical Genetics. Part B. Neuropsychiatric Genetics 2006, 141:323-331.
4. Basile V.S., Masellis M., Potkin S.G., Kennedy J.L. Pharmacogenomics in schizophrenia: the quest for individualized therapy. Human Molecular Genetics 2002, 11:2517-2530.
5. Bellgrove M.A., Hawi Z, Kirley A, Fitzgerald M., Gill M., Robertson I.H. Association between dopamine transporter (DAT1) genotype, left-sided inattention, and an enhanced response to methylphenidate in attention-deficit hyperactivity disorder. Neuropsychopharmacology 2005, 30:2290-2297.
6. Blum K., Chen T.J.H., Bailey J., Bowirrat A., Femino J., Chen A.L.C., Simpatico T., Morse S., Giordano J., Damle U., Kerner M., Braverman E.R., Fornari F., Downs B.W., Rector C., Barh D., Oscar-Berman M. Can the chronic administration of the combination of buprenorphine and naloxone block dopaminergic activity causing anti-reward and relapse potential?. Molecular Neurobiology 2011, 44(3):250-268.
7. Blum K., Chen A.L., Giordano J., Borsten J., Chen T.J., Hauser M., Simpatico T., Femino J., Braverman E.R., Barh D. The addictive brain: all roads lead to dopamine. Journal of Psychoactive Drugs 2012, 44(2):134-143.
8. Bodkin J.A., Zornberg G.L., Lukas S.E., Cole J.O. Buprenorphine treatment of refractory depression. Journal of Clinical Psychopharmacology 1995, 15:49-57.
9. Chefer V.I., Czyzyk T., Bolan E.A., Moron J., Pintar J.E., Shippenberg T.S. Endogenous kappa-opioid receptor systems regulate mesoaccumbal dopamine dynamics and vulnerability to cocaine. Journal of Neuroscience 2005, 25:5029-5037.
10. Chen A.C., LaForge K.S., Ho A., McHugh P.F., Kellogg S., Bell K., Schluger R.P., Leal S.M., Kreek M.J. Potentially functional polymorphism in the promoter region of prodynorphin gene may be associated with protection against cocaine dependence or abuse. American Journal of Medical Genetics 2002, 114:429-435.
11. Connock M., Juarez-Garcia A., Jowett S., Frew E., Liu Z., Taylor R.J., Fry-Smith A., Day E., Lintzeris N., Roberts T., Burls A., Taylor R.S. Methadone and buprenorphine for the management of opioid dependence: a systematic review and economic evaluation. Health Technology Assessment 2007, 11:1-171.
12. Cornish K.M., Manly T., Savage R., Swanson J., Morisano D., Butler N., Grant C., Cross G., Bentley L., Hollis C.P. Association of the dopamine transporter (DAT1) 10/10-repeat genotype with ADHD symptoms and response inhibition in a general population sample. Molecular Psychiatry 2005, 10:686-698.
13. Cornish K.M., Savage R., Hocking D.R., Hollis C.P. Association of the DAT1 genotype with inattentive behavior is mediated by reading ability in a general population sample. Brain and Cognition 2011, 77(3):453-458.
14. Drgon T., Lin Z., Wang G.J., Fowler J., Pablo J., Mash D.C., Volkow N., Uhl GR. Common human 5' dopamine transporter (SLC6A3) haplotypes yield varying expression levels in vivo. Cell and Molecular Neurobiology 2006, 26:875-889.
15. Fava M., Guaraldi G.B., Mazzi F., Rigatelli M. Intervista Clinica Strutturata per il DSM-III-R. 1993, Organizzazioni Speciali, Florence.
16. Fuke S., Suo S., Takahashi N., Koike H., Sasagawa N., Ishiura S. The VNTR polymorphism of the human dopamine transporter (DAT1) gene affects gene expression. Pharmacogenomics Journal 2001, 1(2):152-156.
17. Gerra G., Borella F., Zaimovic A., Moi G., Bussandri M., Bubici C., Bertacca S. Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug and Alcohol Dependence 2004, 75:37-45.
18. Gerra G., Garofano L., Pellegrini C., Bosari S., Zaimovic A., Moi G., Avanzino P., Malarico E., Gardini F., Donnini C. Allelic association of a dopamine transporter gene polymorphism with antisocial behavior in heroin-dependent patients. Addiction Biology 2005, 10:275-281.
19. Gerra G., Leonardi C., D'Amore A., Strepparola G., Fagetti R., Assi C., Zaimovic A., Lucchini A. Buprenorphine treatment outcome in dually diagnosed heroin dependent patients: a retrospective study. Progress in Neuropharmacology and Biological Psychiatry 2006, 30:265-272.
20. Gerra G., Leonardi C., Cortese E., D'Amore A., Lucchini A., Strepparola G., Serio G., Farina G., Magnelli F., Zaimovic A., Mancini A., Turci M., Manfredini M., Donnini C. Human kappa opioid receptor gene (OPRK1) polymorphism is associated with opiate addiction. American Journal of Medical Genetics. Part B. Neuropsychiatric Genetics 2007, 144:771-775.
21. Gulley J.M., Zahniser N.R. Rapid regulation of dopamine transporter function by substrates, blockers and presynaptic receptor ligands. European Journal of Pharmacology 2003, 479:139-152.
22. Haasen C., van den Brink W Innovations in agonist maintenance treatment of opioid-dependent patients. Current Opinion in Psychiatry 2006, 19:631-636.
23. Kelada S.N., Costa-Mallen P., Checkoway H., Carlson C.S., Weller T.S., Swanson P.D., Franklin G.M., Longstreth W.T., Afsharinejad Z., Costa L.G. Dopamine transporter (SLC6A3) 5' region haplotypes significantly affect transcriptional activity in vitro but are not associated with Parkinson's disease. Pharmacogenetics and Genomics 2005, 15:659-668.
24. Kirley A., Lowe N., Hawi Z., Mullins C., Daly G., Waldman I., McCarron M., O'Donnell D., Fitzgerald M., Gill M. Association of the 480bp DAT1 allele with methylphenidate response in a sample of Irish children with ADHD. American Journal of Medical Genetics. Part B. Neuropsychiatric Genetics 2003, 121:50-54.
25. Kosten T.R., Morgan C., Kosten T.A. Depressive symptoms during buprenorphine treatment of opioid abusers. Journal of Substance Abuse Treatment 1990, 7:51-54.
26. Larntz K. Small-sample comparisons of exact levels for chi-squared goodness-of-fit statistics. Journal of the American Statistical Association 1978, 73:253-263.
27. Lawford B.R, Young R.M., Noble E.P., Sargent J., Rowell J., Shadforth S., Zhang X., Ritchie T. The D(2) dopamine receptor A(1) allele and opioid dependence: association with heroin use and response to methadone treatment. American Journal of Medical Genetics 2000, 96:592-598.
28. Lee S.S., Lahey B.B., Waldman I., Van Hulle C.A., Rathouz P., Pelham W.E., Loney J., Cook E.H. Association of dopamine transporter genotype with disruptive behavior disorders in an eight-year longitudinal study of children and adolescents. American Journal of Medical Genetics. Part B. Neuropsychiatric Genetics 2007, 144:310-317.
29. Lötsch J., Stuck B., Hummel T. The human mu-opioid receptor gene polymorphism 118A>G decreases cortical activation in response to specific nociceptive stimulation. Behavioral Neuroscience 2006, 120:1218-1224.
30. Maffei C., Fossati A., Agostani I., Barraco A., Bagnato M., Deborah D., Namia C., Novella L., Petrachi M. Interrater reliability and internal consistency of the structured clinical interview for DSM-IV axis II personality disorders (SCID-II), version 2.0. Journal of Personality Disorders 1997, 11:279-284.
31. Mannuzza S., Klein R.G., Bessler A., Malloy P., LaPadula M. Adult outcome of hyperactive boys. Educational achievement, occupational rank, and psychiatric status. Archives of General Psychiatry 1993, 50:565-576.
32. Mattick R.P., Kimber J., Breen C., Davoli M. Buprenorphine maintenance versus placebo or methadone maintenance for opioid dependence. The Cochrane Database of Systematic Reviews 2003, 2:CD002207.
33. Modestin J., Matutat B., Würmle O. Antecedents of opioid dependence and personality disorder: attention-deficit/hyperactivity disorder and conduct disorder. European Archives of Psychiatry and Clinical Neuroscience 2001, 251:42-47.
34. Nantwi K.D., Hicks S., Bradley D, Schoener EP. Interactions of buprenorphine and selective dopamine receptor antagonists in the rat nucleus accumbens. General Pharmacology 1998, 31:425-429.
35. Petitjean S., Stohler R., Déglon J.J., Livoti S., Waldvogel D., Uehlinger C., Ladewig D. Double-blind randomized trial of buprenorphine and methadone in opiate dependence. Drug and Alcohol Dependence 2001, 62:97-104.
36. Pfohl B., Blum N., Zimmerman M., Stangl D. Structured Interview for Personality Disorders, revised version 1989, University of Iowa, Iowa City, IA.
37. Poirier MF., Laqueille X., Jalfre V., Willard D., Bourdel M.C., Fermanian J., Olié JP. Clinical profile of responders to buprenorphine as a substitution treatment in heroin addicts: results of a multicenter study of 73 patients. Progress in Neuropharmacology and Biological Psychiatry 2004, 28:267-272.
38. Resnick R.B., Resnick E., Galanter M. Buprenorphine responders: a diagnostic subgroup of heroin addicts?. Progress in Neuropharmacology and Biological Psychiatry 1991, 15:531-538.
39. Robinson S.E. Buprenorphine: an analgesic with an expanding role in the treatment of opioid addiction. CNS Drug Reviews 2002, 8:377-390.
40. Rothman R.B., Gorelick D.A., Heishman S.J., Eichmiller P.R., Hill B.H., Norbeck J., Liberto J.G. An open-label study of a functional opioid kappa antagonist in the treatment of opioid dependence. Journal of Substance Abuse Treatment 2000, 18:277-281.
41. Sorge R.E., Stewart J. The effects of chronic buprenorphine on intake of heroin and cocaine in rats and its effects on nucleus accumbens dopamine levels during self-administration. Psychopharmacology (Berl) 2006, 188:28-41.
42. Spitzer R.L., Williams J.B.W., Gibbon M., First M.B. Structured Clinical Interview According to DSM-III-R 1990, American Psychiatric Press, Washington, DC.
43. Strain E.C., Stitzer M.L., Liebson I.A., Bigelow G.E. Buprenorphine versus methadone in the treatment of opioid dependence: self-reports, urinalysis, and addiction severity index. Journal of Clinical Psychopharmacology 1996, 16:58-67.
44. Strain E.C., Bigelow G.E., Liebson IA., Stitzer M.L. Moderate-vs. high-dose methadone in the treatment of opioid dependence: a randomized trial. JAMA:Journal of the American Medical Association 1999, 281:1000-1005.
45. Svingos A.L., Chavkin C., Colago E.E., Pickel V.M. Major coexpression of kappa-opioid receptors and the dopamine transporter in nucleus accumbens axonal profiles. Synapse 2001, 42:185-192.
46. Thompson A.C., Zapata A., Justice J.B., Vaughan R.A., Sharpe L.G., Shippenberg T.S. Kappa-opioid receptor activation modifies dopamine uptake in the nucleus accumbens and opposes the effects of cocaine. Journal of Neuroscience 2000, 20:9333-9340.
47. van de Giessen E., de Win MM., Tanck MW., van den Brink W., Baas F., Booij J. Striatal dopamine transporter availability associated with polymorphisms in the dopamine transporter gene SLC6A3. Journal of Nuclear Medicine 2009, 50(1):45-62.
48. Vandenbergh D.J., Persico A.M., Hawkins A.L., Griffin C.A., Li X., Jabs E.W., Uhl G.R. Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR. Genomics 1992, 14:1104-1106.
49. Yuferov V., Fussell D., LaForge K.S., Nielsen D.A., Gordon D., Ho A., Leal S.M., Ott J., Kreek MJ. Redefinition of the human kappa opioid receptor gene (OPRK1) structure and association of haplotypes with opiate addiction. Pharmacogenetics 2004, 14:793-804.
50. Yang B., Chan R.C., Jing J., Li T., Sham P., Chen R.Y. A meta-analysis of association studies between the 10-repeat allele of a VNTR polymorphism in the 3'-UTR of dopamine transporter gene and attention deficit hyperactivity disorder. American Journal of Medical Genetics. Part B. Neuropsychiatric Genetics 2007, 144:541-550.